RenovoRx (RNXT) Net Equity Issued and Repurchased (2021 - 2026)
RenovoRx (RNXT) posted Net Equity Issued and Repurchased of $10.0 million for Q1 2026, down 17.37% sequentially from $12.1 million in Q1 2025, and down 17.37% YoY from $12.1 million in Q1 2025.
RenovoRx (RNXT) Net Equity Issued and Repurchased (2021 - 2026) Analysis & Trends
RenovoRx has reported Net Equity Issued and Repurchased for 3 years, with the latest figure at $10.0 million in Q1 2026.
- Quarterly Net Equity Issued and Repurchased fell 17.37% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.1 million (up 82.6% YoY) and the FY2025 annual result came in at $12.1 million, down 29.84% from the prior year.
- Net Equity Issued and Repurchased declined to $10.0 million in Q1 2026 per RNXT's latest filing, from $12.1 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $12.1 million in Q1 2025 and troughed at $10.0 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | RenovoRx | 62.20 Mn | 62.20 Mn | 766,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.00 Mn |
| Mar 31, 2026 | 10.00 Mn |
| Mar 31, 2025 | 12.10 Mn |
| Mar 31, 2025 | 12.10 Mn |
| Dec 31, 2021 | 2,000.00 |
| Dec 31, 2021 | 2,000.00 |